Lucid Diagnostics Inc. Common Stock
LUCDLucid Diagnostics Inc. is a healthcare company focused on early detection and diagnosis of gastrointestinal cancers. Through its proprietary technology and testing methods, it aims to improve patient outcomes by providing non-invasive, accurate diagnostic solutions for conditions such as esophageal and other gastrointestinal cancers.
Company News
PAVmed Inc. announced a 1-for-30 reverse stock split effective January 2, 2026, to comply with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and authorized shares will be reduced from 250 million to 25 million. The company's stock will continue trading under symbol PAVM on Nasdaq Capital...
Lucid Diagnostics will host a business update conference call on November 12, 2025, at 8:30 AM ET, where CEO Lishan Aklog will discuss company operations and growth strategy, and CFO Dennis McGrath will review Q3 2025 financial results.
Lucid Diagnostics, a cancer prevention medical diagnostics company, announced plans for a public stock offering to support working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners.
PAVmed, a diversified medical technology company, will host a business update conference call and webcast on November 14, 2024, to discuss its third quarter 2024 financial results and provide an overview of its operations and growth strategy.
The article highlights four promising penny stocks with high-risk, high-reward potential: Allurion Technologies, Lucid Diagnostics, KULR Technology Group, and Gevo. These companies operate in diverse industries, including weight loss management, medical diagnostics, sustainable energy, and renewable fuels.
